Tag: wet AMD
Regeneron sales boom with drug launch
Regeneron Pharmaceuticals in Greenburgh raised its 2012 sales forecast for its year-old drug Eylea by $90 million to $115 million over its earlier forecast.
Regeneron Takes Top Spot in Science Magazine Survey
Regeneron Pharmaceuticals Inc., long considered to be the cornerstone of a fast-emerging biotechnology cluster here in the Hudson Valley, was ranked the number one employer in the global biopharmaceutical industry by Science magazine.
Eylea approved for use in Japan
Regeneron Pharmaceuticals Inc. announced today that Eylea was approved for the treatment of patients with neovascular, or wet, age-related macular degeneration (AMD) in Japan.
